Evoke Pharma, Inc. Files $24 Million IPO
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Evoke Pharma (NASDAQ: EVOK) filed a $24 million IPO on form S-1 with the SEC this afternoon. The company plans to list its shares on the NASDAQ under the trading symbol "EVOK." Aegis Capital is the lone underwriter at this point. Evoke Pharma is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. The company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.
Help employers find you! Check out all the jobs and post your resume.
Evoke Pharma (NASDAQ: EVOK) filed a $24 million IPO on form S-1 with the SEC this afternoon. The company plans to list its shares on the NASDAQ under the trading symbol "EVOK." Aegis Capital is the lone underwriter at this point. Evoke Pharma is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. The company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.
Help employers find you! Check out all the jobs and post your resume.